SCHEMBL7801729

SCHEMBL7801729

COc1ccc(Oc2cccc(Oc3ccc4c(c3)OCO4)c2C(=O)O)cc1OC

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.57
ALDH1A1 P00352 1/20 0.52
NPC1 O15118 8/20 0.48
RAB9A P51151 7/20 0.48
SMN1; SMN2 Q16637 2/20 0.47
TP53 P04637 2/20 0.47
PKM P14618 1/20 0.47
MAPT P10636 3/20 0.47
LMNA P02545 1/20 0.47
CA12 O43570 1/20 0.47
CA1 P00915 1/20 0.47
CA2 P00918 1/20 0.47
CA7 P43166 1/20 0.47
CA9 Q16790 1/20 0.47
CA14 Q9ULX7 1/20 0.47
EDNRA P25101 1/20 0.46
MEN1 O00255 1/20 0.46
POLB P06746 1/20 0.45
ACHE P22303 1/20 0.45
TSHR P16473 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8544701 1.00 KMT2A (0.57) KMT2AALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL7800904 0.90 NPC1 (0.50) KMT2AALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL795101 0.90 MAOB (0.50) KMT2AALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL7802114 0.89 KMT2A (0.55) KMT2AALDH1A1NPC1RAB9AEDNRA
SCHEMBL8547479 0.85 NPC1 (0.47) KMT2AALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL7799665 0.85 NPC1 (0.47) KMT2AALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL7791690 0.84 ALDH1A1 (0.50) KMT2AALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL7791683 0.84 RAB9A (0.47) KMT2AALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL7791782 0.83 ALDH1A1 (0.41) KMT2AALDH1A1NPC1RAB9ATDP1
SCHEMBL7791788 0.82 KMT2A (0.43) KMT2AALDH1A1NPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5977117-A Substituted phenyl compounds and derivatives thereof that modulate the activity of endothelin TEXAS BIOTECHNOLOGY CORPORATION (US) 1999-11-02 US claimed
US-20010014694-A1 Substituted phenyl compounds and derivatives thereof that modulate the activity of endothelin ENCYSIVE PHARMACEUTICALS, INC. 2001-08-16 US disclosed
US-6265428-B1 VASODILATION TEXAS BIOTECHNOLOGY CORPORATION 2001-07-24 US disclosed
US-5977117-A Substituted phenyl compounds and derivatives thereof that modulate the activity of endothelin TEXAS BIOTECHNOLOGY CORPORATION (US) 1999-11-02 US disclosed
EP-0876364-A2 SUBSTITUTED PHENYL COMPOUNDS AND DERIVATIVES THEREOF THAT MODULATE THE ACTIVITY OF ENDOTHELIN TEXAS BIOTECHNOLOGY CORPORATION (US) 1998-11-11 EP disclosed
WO-1997025321-A2 SUBSTITUTED PHENYL COMPOUNDS AND DERIVATIVES THEREOF THAT MODULATE THE ACTIVITY OF ENDOTHELIN TEXAS BIOTECHNOLOGY CORPORATION (US) 1997-07-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010014694-A1 Substituted phenyl compounds and derivatives thereof that modulate the activity of endothelin EDNRA, EDNRB, NPR1 KMT2A 3982/4885ALDH1A1 4421/4885NPC1 2650/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.